You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023222013
Dec 20234805
Jan 20244103
Feb 20244603
Mar 20244605
Apr 20244202
May 20243800
Jun 20241800
Jul 20244401
Aug 20241401
Sep 20242805
Oct 20242802
Nov 20243604
Dec 20242603
Jan 20253806
Feb 2025602
Mar 2025003
Apr 2025001
May 2025002
Jun 2025104
Total722065